Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review

K Seppi, K Ray Chaudhuri, M Coelho… - Movement …, 2019 - Wiley Online Library
Objective To update evidence‐based medicine recommendations for treating nonmotor
symptoms in Parkinson's disease (PD). Background The International Parkinson and …

Functional dyspepsia: diagnostic and therapeutic approaches

GS Sayuk, CP Gyawali - Drugs, 2020 - Springer
Functional dyspepsia is a common functional gastrointestinal (GI) disorder of
gastroduodenal origin, diagnosed clinically in the presence of prototypical symptoms of …

[HTML][HTML] A deep learning platform to assess drug proarrhythmia risk

R Serrano, DAM Feyen, AAN Bruyneel, AP Hnatiuk… - Cell Stem Cell, 2023 - cell.com
Drug safety initiatives have endorsed human iPSC-derived cardiomyocytes (hiPSC-CMs) as
an in vitro model for predicting drug-induced cardiac arrhythmia. However, the extent to …

ABM Clinical Protocol# 9: Use of galactogogues in initiating or augmenting maternal milk production, second revision 2018

W Brodribb… - Breastfeeding …, 2018 - liebertpub.com
A central goal of the Academy of Breastfeeding Medicine is the development of clinical
protocols for managing common medical problems that may impact breastfeeding success …

Virtual screening of DrugBank database for hERG blockers using topological Laplacian-assisted AI models

H Feng, GW Wei - Computers in biology and medicine, 2023 - Elsevier
The human ether-a-go-go (hERG) potassium channel (K v 11. 1) plays a critical role in
mediating cardiac action potential. The blockade of this ion channel can potentially lead fatal …

[HTML][HTML] A review of medical therapy for proton pump inhibitor nonresponsive gastroesophageal reflux disease

L Hillman, R Yadlapati, AJ Thuluvath… - Diseases of the …, 2017 - ncbi.nlm.nih.gov
Up to 40% of patients report persistent gastroesophageal reflux disease (GERD) symptoms
despite proton pump inhibitor (PPI) therapy. This review outlines the evidence for medical …

[HTML][HTML] Evaluation and management of esophageal manifestations in systemic sclerosis

K Denaxas, SD Ladas… - Annals of …, 2018 - ncbi.nlm.nih.gov
Systemic sclerosis (SSc) is a multisystemic autoimmune connective tissue disorder; in the
gastrointestinal tract, the esophagus is the most commonly affected organ. Symptoms of …

Domperidone to treat symptoms of gastroparesis: benefits and side effects from a large single-center cohort

R Schey, M Saadi, D Midani, AC Roberts… - Digestive diseases and …, 2016 - Springer
Background There is increased awareness about risks and benefits of using domperidone to
treat gastroparesis. Aim To describe the outcome of treating patients with refractory …

Domperidone and the risks of sudden cardiac death and ventricular arrhythmia: A systematic review and meta‐analysis of observational studies

LB Ou, C Moriello, A Douros… - British Journal of Clinical …, 2021 - Wiley Online Library
Aims Concerns exist regarding the cardiovascular safety of domperidone. However, many of
the previous studies addressing this issue had important limitations. We aimed to examine …

Management of ineffective esophageal hypomotility

S Jandee, A Geeraerts, H Geysen, N Rommel… - Frontiers in …, 2021 - frontiersin.org
Esophageal hypomotility in general and especially ineffective esophageal motility according
to the Chicago criteria of primary motility disorders of the esophagus, is one of the most …